JP7330667B2 - ゴールドキウイフルーツ組成物ならびにその調製および使用方法 - Google Patents
ゴールドキウイフルーツ組成物ならびにその調製および使用方法 Download PDFInfo
- Publication number
- JP7330667B2 JP7330667B2 JP2017547368A JP2017547368A JP7330667B2 JP 7330667 B2 JP7330667 B2 JP 7330667B2 JP 2017547368 A JP2017547368 A JP 2017547368A JP 2017547368 A JP2017547368 A JP 2017547368A JP 7330667 B2 JP7330667 B2 JP 7330667B2
- Authority
- JP
- Japan
- Prior art keywords
- kiwifruit
- gold
- pharmaceutical composition
- powder
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000298697 Actinidia deliciosa Species 0.000 title claims description 199
- 235000009436 Actinidia deliciosa Nutrition 0.000 title claims description 197
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims description 192
- 239000010931 gold Substances 0.000 title claims description 188
- 229910052737 gold Inorganic materials 0.000 title claims description 188
- 239000000203 mixture Substances 0.000 title claims description 188
- 238000000034 method Methods 0.000 title description 70
- 238000002360 preparation method Methods 0.000 title description 7
- 239000000843 powder Substances 0.000 claims description 97
- 241000605980 Faecalibacterium prausnitzii Species 0.000 claims description 67
- 206010010774 Constipation Diseases 0.000 claims description 60
- 235000013824 polyphenols Nutrition 0.000 claims description 60
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 55
- 230000001965 increasing effect Effects 0.000 claims description 39
- 239000002775 capsule Substances 0.000 claims description 38
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 38
- 235000013406 prebiotics Nutrition 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 30
- 239000006041 probiotic Substances 0.000 claims description 25
- 235000018291 probiotics Nutrition 0.000 claims description 25
- 235000013325 dietary fiber Nutrition 0.000 claims description 21
- 230000000529 probiotic effect Effects 0.000 claims description 21
- 230000001079 digestive effect Effects 0.000 claims description 20
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 20
- 208000024891 symptom Diseases 0.000 claims description 19
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 17
- 235000009434 Actinidia chinensis Nutrition 0.000 claims description 15
- 102000038379 digestive enzymes Human genes 0.000 claims description 15
- 108091007734 digestive enzymes Proteins 0.000 claims description 15
- 235000019722 synbiotics Nutrition 0.000 claims description 15
- 230000000968 intestinal effect Effects 0.000 claims description 13
- 235000015110 jellies Nutrition 0.000 claims description 11
- 244000298715 Actinidia chinensis Species 0.000 claims description 9
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 238000011260 co-administration Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 description 48
- 241000894006 Bacteria Species 0.000 description 44
- 230000009286 beneficial effect Effects 0.000 description 41
- 230000033001 locomotion Effects 0.000 description 39
- 230000000694 effects Effects 0.000 description 32
- 241000736262 Microbiota Species 0.000 description 30
- 230000029087 digestion Effects 0.000 description 30
- 235000013399 edible fruits Nutrition 0.000 description 25
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 23
- 230000001580 bacterial effect Effects 0.000 description 22
- 230000012010 growth Effects 0.000 description 21
- 241000186000 Bifidobacterium Species 0.000 description 19
- 230000000813 microbial effect Effects 0.000 description 19
- 241000186660 Lactobacillus Species 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000000835 fiber Substances 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 108090000350 actinidain Proteins 0.000 description 16
- 238000004108 freeze drying Methods 0.000 description 16
- 229940039696 lactobacillus Drugs 0.000 description 16
- 150000007524 organic acids Chemical class 0.000 description 16
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 238000003753 real-time PCR Methods 0.000 description 16
- ZHQQRIUYLMXDPP-SSDOTTSWSA-N Actinidine Natural products C1=NC=C(C)C2=C1[C@H](C)CC2 ZHQQRIUYLMXDPP-SSDOTTSWSA-N 0.000 description 15
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 108020004465 16S ribosomal RNA Proteins 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 244000005700 microbiome Species 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 13
- 230000036541 health Effects 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- -1 quercetin rhamnoside Chemical class 0.000 description 13
- 241000606125 Bacteroides Species 0.000 description 12
- 208000018522 Gastrointestinal disease Diseases 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 238000000855 fermentation Methods 0.000 description 12
- 230000004151 fermentation Effects 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 150000002989 phenols Chemical class 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 239000013589 supplement Substances 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 11
- 210000001072 colon Anatomy 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 230000002550 fecal effect Effects 0.000 description 11
- 239000008141 laxative Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- XFZJEEAOWLFHDH-NFJBMHMQSA-N procyanidin B2 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-NFJBMHMQSA-N 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 230000009469 supplementation Effects 0.000 description 10
- 241001134638 Lachnospira Species 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 235000014633 carbohydrates Nutrition 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 229940032147 starch Drugs 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 241000186560 Blautia coccoides Species 0.000 description 8
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000000112 colonic effect Effects 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 206010016766 flatulence Diseases 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000002475 laxative effect Effects 0.000 description 8
- 235000005985 organic acids Nutrition 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 210000002249 digestive system Anatomy 0.000 description 7
- 208000010643 digestive system disease Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 244000005709 gut microbiome Species 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 229940125722 laxative agent Drugs 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 150000004666 short chain fatty acids Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 6
- 241000606124 Bacteroides fragilis Species 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 229920001202 Inulin Polymers 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000018685 gastrointestinal system disease Diseases 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 6
- 229940029339 inulin Drugs 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 206010000060 Abdominal distension Diseases 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 229920002350 Procyanidin B2 Polymers 0.000 description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 5
- 241000123753 Ruminococcus bromii Species 0.000 description 5
- 241000192026 Ruminococcus flavefaciens Species 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 208000024330 bloating Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000013872 defecation Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000004817 gas chromatography Methods 0.000 description 5
- 230000007407 health benefit Effects 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000004537 pulping Methods 0.000 description 5
- 235000005875 quercetin Nutrition 0.000 description 5
- 229960001285 quercetin Drugs 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 235000021391 short chain fatty acids Nutrition 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 4
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 4
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 4
- 241001112695 Clostridiales Species 0.000 description 4
- 241000193403 Clostridium Species 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- 241000792859 Enema Species 0.000 description 4
- 241001608234 Faecalibacterium Species 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 4
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 4
- 235000005487 catechin Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229940074393 chlorogenic acid Drugs 0.000 description 4
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 4
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 4
- 235000001368 chlorogenic acid Nutrition 0.000 description 4
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 239000007920 enema Substances 0.000 description 4
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 4
- 235000012734 epicatechin Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000005095 gastrointestinal system Anatomy 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 229920002581 Glucomannan Polymers 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 229940126902 Phlorizin Drugs 0.000 description 3
- 244000134552 Plantago ovata Species 0.000 description 3
- 235000003421 Plantago ovata Nutrition 0.000 description 3
- 239000009223 Psyllium Substances 0.000 description 3
- 244000299790 Rheum rhabarbarum Species 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 3
- 235000019647 acidic taste Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000011399 aloe vera Nutrition 0.000 description 3
- 229940025131 amylases Drugs 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002036 drum drying Methods 0.000 description 3
- 230000007140 dysbiosis Effects 0.000 description 3
- 229940079360 enema for constipation Drugs 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229940046240 glucomannan Drugs 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 3
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 description 3
- 235000019139 phlorizin Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229940070687 psyllium Drugs 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000005070 ripening Effects 0.000 description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000015961 tonic Nutrition 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 2
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 241001135228 Bacteroides ovatus Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241001183186 Fusobacteriaceae Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 240000006240 Linum usitatissimum Species 0.000 description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 241001668545 Pascopyrum Species 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 241000192031 Ruminococcus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 241000186569 [Clostridium] leptum Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000004922 colonic epithelial cell Anatomy 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000004426 flaxseed Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 230000007366 host health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 230000007269 microbial metabolism Effects 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 238000000424 optical density measurement Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229930015704 phenylpropanoid Natural products 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- FHYIXLQAMONDNN-UXPWSPDFSA-N (2S)-6-amino-2-[[(2S)-2-[[(2R)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]-N-(4-methyl-2-oxochromen-7-yl)hexanamide Chemical compound CC1=CC(=O)OC2=CC(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](C)N)CC(C)C)=CC=C21 FHYIXLQAMONDNN-UXPWSPDFSA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000702460 Akkermansia Species 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 1
- 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606126 Bacteroidaceae Species 0.000 description 1
- 241000692822 Bacteroidales Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193452 Clostridium tyrobutyricum Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241001302654 Escherichia coli Nissle 1917 Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010056325 Faecaloma Diseases 0.000 description 1
- 208000008415 Fecal Impaction Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 235000012068 Feijoa sellowiana Nutrition 0.000 description 1
- 244000233576 Feijoa sellowiana Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010017367 Frequent bowel movements Diseases 0.000 description 1
- 241000605975 Fusobacterium varium Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101100102135 Human cytomegalovirus (strain AD169) US35 gene Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241001134640 Lachnospira multipara Species 0.000 description 1
- 241001112693 Lachnospiraceae Species 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000254697 Lactobacillus rhamnosus HN001 Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- QRKUHYFDBWGLHJ-UHFFFAOYSA-N N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide Chemical compound FC(F)(F)C(=O)N(C)[Si](C)(C)C(C)(C)C QRKUHYFDBWGLHJ-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000606752 Pasteurellaceae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 229920000385 Procyanidin B1 Polymers 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 241000589615 Pseudomonas syringae Species 0.000 description 1
- 201000000660 Pyloric Stenosis Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000605947 Roseburia Species 0.000 description 1
- 241000398180 Roseburia intestinalis Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 101150049278 US20 gene Proteins 0.000 description 1
- 101150116905 US23 gene Proteins 0.000 description 1
- 101150077766 US30 gene Proteins 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 241001430183 Veillonellaceae Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 206010069085 atrophic glossitis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 229940022777 azasan Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940029830 benefiber Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940095498 calcium polycarbophil Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940088516 cipro Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000002548 cytokinetic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000001064 degrader Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001729 effect on metabolism Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000008144 emollient laxative Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 229940104788 entyvio Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 208000019064 esophageal ulcer Diseases 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940063190 flagyl Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940062737 gengraf Drugs 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 235000021192 high fiber diet Nutrition 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940042003 metamucil Drugs 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical group Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940095353 oral granules Drugs 0.000 description 1
- 229940042126 oral powder Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940072223 pentasa Drugs 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- XFZJEEAOWLFHDH-UKWJTHFESA-N procyanidin B1 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UKWJTHFESA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 229940069591 purixan Drugs 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 235000015032 reconstituted 100% juice Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003979 response to food Effects 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940063122 sandimmune Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 229940068638 simponi Drugs 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229940071598 stelara Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940075430 wheat dextrin Drugs 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本出願は2014年11月28日出願のニュージーランド特許出願第702454号、および2015年3月27日出願のニュージーランド特許出願第706405号の利益を主張するもので、各々の内容は、その全体が参照により本明細書に組み込まれる。
本開示は、ゴールドキウイフルーツ(アクティニディア・キネンシス(Actinidia chinensis))から調製した組成物に関する。また、かかる組成物の調製方法と、胃腸器疾患の治療または予防方法を含む使用方法にも関する。
胃腸管には、1000を超える種族や系統型から成る、およそ1014個の微生物細胞が存在し、その大部分が結腸に生存している(Rajilic-Stojanovic and de Vosm 2014年、Qin他 2010年、Egert他 2006年)。発酵が発生する大腸は代謝が活発で、ヒトの健康に不可欠な、微生物の多様で複雑な関係性によって特徴づけられる(Backhed他 2005年)。これまで、実験のデータにより、結腸の微生物相とそれを宿すヒトが微妙な平衡状態で存在する程度が示されている。この微生物相には、幅広い健康上の利益との関連性が示されており、その例としては免疫機能の改善や成熟、行動の変化、満腹感の抑制、病原の阻害、ミネラルの吸収促進、エネルギーバランスの吸収および維持が挙げられる(Geurts他 2014年、Parnell and Reimer 2012年、Bravo他 2011年、Buffie and Pamer 2013年)。
a)ゴールド3の品種またはその遺伝的派生品種であるゴールドキウイフルーツを取得することと、
b)キウイフルーツの皮を取り除き、1mm未満の大きさのふるいでピューレ状にすることと、
c)ピューレを乾燥させ、粉末を生成することと、を含む。
本方法は、ピューレ状にする前にキウイフルーツの種を取り除くことを更に含む。
本方法は、キウイをピューレ状にして、16°~21°のブリックス値を有するピューレを取得することを更に含む。
本方法は、組成物のポリフェノール含有量を高めることを更に含む。
本方法は、組成物にポリフェノールを添加することを更に含む。
本方法は、40時間から56時間かけてピューレを凍結乾燥させることを更に含む。
もう1つの態様において、本発明は、ゴールド3品種またはその遺伝的派生品種である乾燥させたゴールドキウイフルーツから調製された組成物を含む。この粉末は前述の態様のいずれかの方法で生成されうる。
組成物は腸内投与用に調合される。
組成物は経口投与用に調合される。
上記カプセルはゲルカプセルである。
上記錠剤またはカプセルは400mg~800mgの粉末を含むように調合される。
組成物は液体として調合される。
上記液体は投与単位あたり400~800mgの粉末を含む。
組成物は更なる消化補助剤との組み合わせにて調合される。
組成物は、1つ以上のプレバイオティクス、プロバイオティクス、またはシンバイオティクス組成物との組み合わせにて調合される。
組成物にポリフェノールが補足される。
もう1つの態様において、本発明は、便秘を治療もしくは予防し、または腸の調整を維持もしくは改善する方法を含み、該方法は、
前述の態様のいずれかの組成物を対象者に投与することにより、対象者の便秘を治療もしくは予防し、または腸の調整を維持もしくは改善することを含む。
組成物は腸内投与される。
組成物は経口または直腸投与される。
組成物はゼリーまたは分包として投与される。
上記カプセルはゲルカプセルである。
組成物は、一日あたり250mg~2500mgの粉末、またはそれと同価の液体の投与量にて投与される。
組成物は、1つ以上のプロバイオティクス、プレバイオティクス、またはシンバイオティクス組成物と同時投与される。
組成物にポリフェノールが補足される。
もう1つの態様において、本発明は、消化管の微生物叢の不均衡を治療または予防する方法を含み、該方法は、
前述の態様のいずれかの組成物を対象者に投与することにより、対象者の消化管の微生物叢の不均衡を治療または予防することを含む。
組成物は腸内投与される。
組成物は経口または直腸投与される。
組成物はゼリーまたは分包として投与される。
上記カプセルはゲルカプセルである。
組成物は、一日あたり250mg~2500mgの粉末、またはそれと同価の液体の投与量にて投与される。
組成物は、1つ以上のプロバイオティクス、プレバイオティクス、またはシンバイオティクス組成物と同時投与される。
組成物にポリフェノールが補足される。
もう1つの態様において、更に本発明は、消化管における有益細菌を保持および増量する方法を含み、該方法は、
前述の態様いずれかの組成物を対象者に投与することにより、対象者の消化管における有益細菌を保持または増量することを含む。
組成物は腸内投与される。
組成物は経口または直腸投与される。
組成物はゼリーまたは分包として投与される。
上記カプセルはゲルカプセルである。
組成物は、一日あたり250mg~2500mgの粉末、またはそれと同価の液体の投与量にて投与される。
組成物は、1つ以上のプロバイオティクス、プレバイオティクス、またはシンバイオティクス組成物と同時投与される。
組成物にポリフェノールが補足される。
有益細菌は、バクテロイデス-プレボテラ-ポルフィロモナス属(Bacteroides-Prevotella-Porphyromonas)の群、ビフィドバクテリウム属、ラクトバチルス属、ラクノスピラ属(Lachnospiraceae)から選択される。
前述の態様のいずれかの組成物を対象者に投与することにより、対象者の消化管におけるフィーカリバクテリウム・プラウスニッツィを保持または増量することを含む。
組成物は、腸内投与、経口投与、または直腸投与により投与される。
組成物は、錠剤、カプセル、液体、ゼリー、または分包のうちの1つ以上として投与される。
組成物は、一日あたり2000~4000mgの粉末、またはそれと同価の液体の投与量にて投与される。
組成物は更なる消化補助剤と同時投与される。
組成物は、食物繊維および/または消化酵素と同時投与される。
対象者は1つ以上の炎症症状を有する。
対象者は、クローン病、潰瘍性結腸炎、過敏性腸症候群、炎症性腸疾患、胃腸がん、アレルギー、アトピー、または糖尿病のうちの1つ以上の症状を有する。
前述の態様のいずれかの組成物を対象者に投与することにより、対象者における過敏性腸症候群または炎症性腸疾患を治療または予防することを含む。
組成物は、腸内投与、経口投与、または直腸投与により投与される。
組成物は、錠剤、カプセル、液体、ゼリー、または分包のうちの1つ以上として投与される。
組成物は、一日あたり2000~4000mgの粉末、またはそれと同価の液体の投与量にて投与される。
組成物は更なる消化補助剤と同時投与される。
組成物は、食物繊維および/または消化酵素と同時投与される。
もう1つの態様において、本発明は、以下を目的とした医薬品の調製のための、前述の態様のいずれかの組成物の使用を含む。
(ii)対象者における微生物叢不均衡の治療もしくは予防、
(iii)対象者の消化管における有益細菌の保持もしくは増量、
(iv)対象者の消化管におけるフィーカリバクテリウム・プラウスニッツィの保持もしくは増量、または
(v)対象者における過敏性腸症候群もしくは炎症性腸疾患の治療もしくは予防。
本発明の特質とされる新しい特徴は、いずれかの添付図および実施例をともなう本発明の詳細な説明により明らかにされるものである。しかし、本明細書に提示された添付図および実施例は発明を例証し、または発明に対する理解を促すもので、発明の範囲を制限するものではない。
本明細書の各場合において、本発明の説明、実施形態、実施例における「備える」、「含む」などの用語は、限定的でない発展的なものとして読み取られるべきものである。したがって説明および特許請求の範囲で、その前後関係が明らかに要求しない限り、「備える」、「含む」などの言葉は制限されない包括的な、「含むが、これに限定されるものではない」という意味で解釈されるべきものである。
「微生物叢不均衡」(「腸内毒素症」とも呼ばれる)は、消化器系の有益な生物の数が減少、有益な生物の1つ以上の比率が変化、および/または消化器系の有害な生物の数が増大した状態である。有益な生物には、例えば乳酸を生成する細菌や酪酸塩を生成する細菌が含まれうる。有益な生物には以下のものが含まれるが、これに制限されるものではない。ビフィドバクテリウム属菌株、バクテロイデス・フラジリスのようなバクテロイデス科(Bacteroidaceae)菌株、そして大腸菌、例えばクロストリジウム・レプタム(Clostridium leptum)の系統発生群の有効な細菌、例えばフィーカリバクテリウム・プラウスニッツィ。また以下の細菌も含まれる。クロストリジウム・ココイデス、バクテロイデス・テタイオタオミクロン、バクテロイデス・オバトス、バクテロイデス・セルロシリチクス)、ロゼブリア・インテスチナリス、ロゼブリア・イヌリノボランス、ルミノコッカス・ブロミイ、ルミノコッカス・フラベファシエンス。バクテロイデス-プレボテラ-ポルフィロモナス属、ラクノスピラ属、および乳酸菌(Lactobacilli)の有益な生物も含む。有害な生物には以下のものがありうるがこれに限定されない。ブドウ球菌(Staphylococcus)およびサルモネラ菌株(Salmonella)、また以下の科の構成員があげられる:腸内細菌科(Enterobacteriaceae)、パスツレラ科(Pasteurellacaea)、ベイヨネラ科(Veillonellaceae)、フソ細菌科(Fusobacteriaceae)。
本明細書で使用するとき、「対象者」は、ヒトあるいはヒト以外の動物、具体的には、ウシ、ヒツジ、ヤギ、ブタ、馬などの哺乳類と、イヌ、ネコ、その他の飼育されたペットなどの家畜でありうる。
ゴールド3はZespri(登録商標)によって開発されたゴールドキウイフルーツの新品種であり、シュードモナス・シリンガエ病原型アクチニダエ(Pseudomonas syringae pv actinidiae)(Psa、キウイの木の細菌病)への耐性に強く、ニュージーランドではホート16Aに替わるゴールド種として好まれている。ゴールド3品種のキウイフルーツの栄養組成は先品種と類似しており、グリーンキウイフルーツよりアクチニジンおよび食物繊維含有量が低い(表1)。
本発明は概してゴールドキウイフルーツから調製された組成物に関する。特定の態様では、組成物は、アクティニディア・キネンシスから調製される。ゴールドキウイフルーツのゴールド3(別称G3)品種の利用が望ましい。別の態様では、ゴールドキウイフルーツ品種の1つ以上の派生品種を使用することができる。例えばゴールドキウイフルーツ品種の親株を含む遺伝的交雑による一代および二代交配種を使用することが望ましい可能性がある。あるいは親株から得られた変種またはその他の栽培品種の使用もありうる。
本発明者は、ゴールド3品種のゴールドキウイフルーツ粉末が、消化器系の健康を維持し、消化器系の問題および/または消化器疾患を治療および予防するのに役立つ有益な成分を含むことを見出した。本発明者は、ゴールド3品種のゴールドキウイフルーツ粉末が、特に腸の調整を改善するのに有効であることを示した。ゴールド3種の粉末は、有害な細菌よりも有益な細菌の増殖を刺激し、特にフィーカリバクテリウム・プラウスニッツィイの増加をもたらすのにも有効であった。
上記に述べたように、本発明のゴールドキウイフルーツ組成物は、腸内管全体の健康の支持もしくは改善、および/または消化管の多様な状態の治療もしくは予防のために用いることが可能である。多様な状態とは炎症、便秘、微生物叢の不均衡、過敏性腸症候群、および炎症性腸疾患を含む。加えて、本組成物は、腸の調整を維持または改善し、消化管内の(フィーカリバクテリウム・プラウスニッツィイを含む)有益細菌を維持もしくは増加させるのに使用することが可能である。
実施例1:キウイフルーツ粉末の調製
冷凍ゴールドキウイフルーツピューレ(種を除き、冷凍されたゴールドキウイフルーツ還元果汁のピューレ)はニュージーランドのタウランガにある「Kiwifruit Processing Company Ltd」より入手した。ピューレは、Zespri(登録商標)社の出荷基準に適合するよう育成され手作業で選別されたニュージーランドのゴールドキウイフルーツ(アクティニディア・キネンシスG3)100%から作製された。ピューレは、果皮と種を取り除き滑らかで芳醇なピューレを作成するための製造工程によって生産された。
色:キウイフルーツゴールド(若干のバラツキあり)。味:成熟したゴールドキウイフルーツの味。テクスチャー:種がなく滑らか。ピューレは、腐敗もしくは発酵した果実、または異物を含まず、また大腸菌は検出することができない。ブリックス値:16~21°。20℃でブリックス値12.5°の場合の粘度はおよそ12.0であるが収獲年により異なりうる。pH値:3.2~3.8。ふるいサイズは1mm未満。製品は使用時まで-18℃以下で冷凍保存される。
色:キウイフルーツグリーン(若干のバラツキあり)。味:成熟したグリーンキウイフルーツの味。テクスチャー:種がなく滑らか。ピューレは、腐敗もしくは発酵した果実、または異物を含まず、また大腸菌は検出することができない。ブリックス値:13~18°。20℃でブリックス値12.5°の場合の粘度はおよそ12.0であるが収獲年により異なりうる。pH値:3.2~3.8。ふるいサイズは1mm未満。製品は使用時まで-18℃以下で冷凍保存される。
1)冷凍されたゴールド3種のピューレはニュージーランドのタウランガにある「Kiwifruit Processing Company Ltd」より購買した。
実施例2:キウイフルーツ粉末のポリフェノール測定
グリーンキウイフルーツ粉末およびゴールドキウイフルーツ粉末のポリフェノール特性を測定した。凍結乾燥(フリーズドライ)されたグリーン(ヘイワード種)およびゴールド(ゴールド3)のキウイフルーツ粉末は実施例1の方法に従って調製された。
ゴールド3キウイフルーツ粉末はペースト状(ニュージーランド、Cedenco Foods製造)のものに豆澱粉を加え、ドラム乾燥(キウイフルーツ湿重量14.28に対しデンプン1)して得た。5gの粉末サンプルは実施例2の上部消化管模擬環境を使用してインビトロ消化された。
実施例4:キウイフルーツ粉末を試験するための混合発酵モデル
ゴールド3キウイフルーツ粉末はペースト状(ニュージーランド、Cedenco Foods製造)のものに豆澱粉を加え、ドラム乾燥(キウイフルーツ湿重量14.28に対しデンプン1)して得た。5gの粉末サンプルは実施例2に従って消化された。消化されたサンプルは水中で可溶化されて1mLあたり10mgの最終濃度に調整された。
臨床プロトコル概要
この研究は4種類の異なる療法をそれぞれ4週間(療法間に2週間の休薬期間)を受けた参加者に対し二重盲検クロスオーバー無作為化プラセボ比較試験を行うために設計された。臨床試験の概略図を図4に示す。
新聞、ラジオ広告、コミュニティ、地域医療保険委員会(DHB)、カンタベリー大学(クライストチャーチ、ニュージーランド)、リンカーン大学(リンカーン、ニュージーランド)、ニュースレター、一般診療医の診療室へのポスター掲示、および参加者の既存データベース等を通して二つのグループの被験者を募った。
1. 次のうち2つ以上を含む必要がある。a)排便時の少なくとも25%にいきみがある、b)排便時の少なくとも25%が硬くコロコロとした便である、c)排便時の少なくとも25%に肛門の閉塞感もしくは詰まるような感覚がある、d)排便時の少なくとも25%に不完全な排便の感覚がある、e)排便時の少なくとも25%に何らかの補助を必要とする、f)1週間あたりの排便が3回以下である。
3. 過敏性腸症候群の診断基準を満たしていない。
付加条件として、年齢18~60才、BMI19~30k/m2、空腹時血糖値5.6mmol/L以下であり、期間中参加者は(研究用の代替食品以外は)日常的な食生活や運動を維持することが求められた。またメタムシル(登録商標)、ベネファイバー(登録商標)、およびPhloe(商標)等の高食物繊維のサプリメントやキウイフルーツの摂取は禁止され食生活に影響を及ぼすであろう海外旅行も避けるように勧告された。
療法はAnagenix Limited(ウェリントン、ニュージーランド)製のカプセル600mgを4つ使用し行われた。カプセルは療法に関わる秘匿性を高めるために同一のものが用意された(表4)。
実施例6:規則性を改善するための治療の結果
表6に参加者の統計分類を示す。「健康」グループと「機能性便秘」グループの服薬遵守はそれぞれ98%±9と99%±8であった。
概要
実施例5に記載したヒト療法試験を用いて、キウイフルーツ由来のサプリメントが、結腸内微生物構成と代謝に与える影響を確認した。記載したように、この試験では、ACTAZIN(商標)(果肉:緑、アクティニディア・デリシオサ、ヘイワード種)とゴールド(果肉:黄金、アクティニディア・キネンシス、「Zesy002」ゴールド3種)のキウイフルーツ由来サプリメント(Anagenix Ltd製、ウェリントン、ニュージーランド)を食事療法として投与した。これらのカプセルは、キウイフルーツに本来含まれる化合物を保持して処方されるように低温処理されたサプリメントである。調製は上記の実施例1の通りに行われた。
すべての糞便サンプルはドライアイス上でPlant & Food Research社Palmerston North支店に送られ、そこで受容されて-20℃で保管された。250mgの各サンプルが計量され、滅菌されたマイクロチューブに注入された。各サンプルからはMO-BIO PowerSoil(登録商標)DNA Isolation Kit(MO-BIO Laboratories製、カールスバッド、カリフォルニア、USA 12888)を用いてDNAが抽出された。
イルミナ(登録商標)MiSeqシーケンスデータはソフトウェアを使って解析された(Quantitative Insights into Microbial Ecology(QIIME)ソフトウェアバージョン1.8.0、Caporaso他 2010年)。ペアエンドリードを単一の連続したシーケンスにアセンブルするため、少なくとも40bpのオーバーラップで、350bp~500bpのサイズを用いてPANDASeqが使用された(Masella他 2012年)。推定キメラをシーケンスから除去し、USERCHおよびUCLUSTを用いて97%の特定閾値に基づきリードをOperational Taxonomic Unit(OTU)にクラスタリングした(Edgar 2010年)。高速なサンプルのプロセッシングを行い、系統学的、分類学的評価に十分であるサンプルあたりおよそ15,000リードで正規化するために、総リードのサブサンプルが取り出された(Caporaso他 2011年、Schloss他 2012年)。
それぞれの糞便のサンプルの500~1000mg部が清潔なチューブで計量され、1:10の割合でリン酸緩衝生理食塩水(PBS)で希釈された。内部標準(酪酸エチル)は5mMの最終濃度になるように加えられた。有機酸は先述のように、改良された方法でGCを用いて定量化された(Richardson他 1989年)。
stats package(R Studio 2012年)を用いて、R Studioで統計計算を行った。ウィルコクソン符号順位検定は属レベルでの分類間および各処置を行う前と行った後での有機酸の濃度の有意な差異の評価をするために実行された。R Studioのp.adjust内での関数偽発見率(FDR)法を用いた多重比較の修正をした後の0.05未満のP値は有意であると認められた(Benjamini & Hochberg 1995年)。
16S rRNA遺伝子シーケンス
糞便のサンプルに由来する細菌のDNAから増幅した16S rRNA遺伝子の可変領域に対し、高スループットシーケンスを行った。この結果リード数が2630万になった。クオリティのフィルタリング、キメラ除去、およびサブサンプリングを行った後、サンプルごとに平均14879配列(最小14139~最大14999)、合計で372万のリード数が得られた。
今回の研究では、乳酸塩、ギ酸塩、およびイソ吉草酸塩は糞便のサンプルから検出されなかった。健康なグループでは、ゴールドの処置後、ヘキサン酸塩の濃度は0.6μmol/gから0.2μmol/g(P値=0.030)に顕著に減少した(表11)。FCグループでは、プラセボの処置後、コハク酸塩の濃度は2.3μmol/gから1.7μmol/g(P値=0.040)に顕著に減少した(表12)。どの処置においても有機酸の濃度に関する特筆すべき変化はなかった。処置の種類によっては13μmol/gに至るほど増加もしくは減少していた酢酸塩を除いては、各処置の実施以前と以後の定量的な差異は概して緩やかであった。
キウイフルーツ由来のサプリメントを消費した後に、顕著に個体数が変化する細菌のグループが存在することが確認された。健康なグループではゴールド(Gold3)の補給後、クロストリジウム目は2.6%増加したが、この増加との関連は現在も調査中である。ゴールドキウイフルーツをベースにしたゴールドを4週間補給した後、FCグループのフィーカリバクテリウム・プラウスニッツィイの相対個体数は顕著に増加した(3.6%)。
要約
この研究では、ACTAZIN(商標)(2400 mg)およびキウイフルーツのサプリメントであるゴールド(2400 mg)の糞便の細菌濃度に対する影響をヒト介入研究および試験管内での発酵実験の両方において調査した。サンプルの微生物構成におけるキウイフルーツをベースとした介入の影響の測定を目的とした。腸内微生物叢の構成の変化を、過去に得られた既存の16S rRNA遺伝子配列データを補足するリアルタイム定量的ポリメラーゼ連鎖反応(qPCR)によって測定した。上記の実施例7および8を参照。
グリーンキウイフルーツは、結腸環境における微生物環境を変化させる作用を含む、消化器の健康を改善する効果が確認されている(Blatchford他 2015年a、Blatchford他 2015年b、Parkar他 2012年)。これらの恩恵は難消化性炭水化物(DRC)、ポリフェノール、およびビタミンCの生来のレベルに由来すると考えられる(Chan他 2007年、Ferguson & Ferguson 2003年)。ゴールドキウイフルーツの恩恵は、まだはっきりと確立されていない。この研究では既存のヒトの臨床試験(実施例5で説明されている)のサンプルを用いて行われた実験について詳述する。ランダム化二重盲検プラセボ対照クロスオーバー試験を行い、2種類のキウイフルーツ由来成分、ACTAZIN(商標)(グリーンキウイフルーツ)およびゴールド(Gold3ゴールドキウイフルーツ)の、消化器の健康における役割を調査した。
実施例5において詳述されているように、この研究はランダム化二重盲検プラセボ対照クロスオーバー試験を行うものであり、参加者に対して4週間に渡って4種類の異なる処置を施し、各処置の間に2週間のウォッシュアウト期間を設けた。下記の表13の通り、処置の内容を分からなくするために、介入では同じ外観の4 x 600 mgのカプセルが処方された。実施例5も参照。記載したように、粉末化された成分は、それぞれニュージーランドのグリーンキウイフルーツおよびゴールドキウイフルーツから調製された。実施例1および5を参照。
リアルタイム定量的PCRデータの結果は、評価された各細菌グループは時間が経過した後も比較的安定した微生物の性質を持っていることを示す。緩やかな増加または減少が各処置後に観察された。表15では、健康なグループにおける各処置期間の前と処置期間の後の、糞便のサンプルのグラムあたりの計算された平均16S rRNA遺伝子複製数(対数変換)として細菌グループを示すLightCycler(登録商標)480 qPCRのデータおよび標準誤差(SEM)が示されている。表16では、機能性便秘グループにおける各処置期間の前と処置期間の後の、糞便のサンプルのグラムあたりの計算された平均16S rRNA遺伝子複製数(対数変換)として細菌グループを示すLightCycler(登録商標)480 qPCRのデータおよび標準誤差(SEM)が示されている。
Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, Heuvelmans-Jacobs M, Akira S, Nicklin MJ, Ribeiro-Dias F, van den Berg WB 2008. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. Journal of Clinical Investigation 118(1): 205-16.
Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC 2012. Low diversity of the gut microbiota in infants with atopic eczema. J Allergy Clin Immunol 129(2): 434-40, 440 e1-2.
Adaim A. 2010. Investigating the effect of gold kiwifruit consumption on the incidence and symptoms of upper respiratory tract infections in preschool children: a thesis presented in partial fulfilment of the requirements for the degree of Masters of Sciences in Human Nutrition and Human Health, Massey University, Auckland, New Zealand.
Attaluri A, Donahoe R, Valestin J, Brown K, Rao SSC 2011. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Alimentary Pharmacology & Therapeutics 33(7): 822-828.
Bach Knudsen KE, Jorgensen H, Canibe N. Quantification of the absorption of nutrients derived from carbohydrate assimilation: model experiment with catheterised pigs fed on wheat- or oat-based rolls. The British Journal of Nutrition. 2000; 84: 449-58.
Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science. 2005; 307: 1915-20.
Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B-Methodological. 1995; 57: 289-300.
Belenguer A, Holtrop G, Duncan SH, Anderson SE, Calder AG, Flint HJ, et al. Rates of production and utilization of lactate by microbial communities from the human colon. FEMS Microbiol. Ecol. 2011; 77: 107-19.
Bentley-Hewitt KL, Blatchford PA, Parkar SG, Ansell J, Pernthaner A. Digested and fermented green kiwifruit increases human beta-defensin 1 and 2 production in vitro. Plant Foods for Human Nutrition. 2012; 67: 208-14.
Blatchford P, Bentley-Hewitt KL, Stoklosinski H, McGhie T, Gearry R, Gibson G, Ansell J 2015a. In vitro characterisation of the fermentation profile and prebiotic capacity of gold-fleshed kiwifruit. Benef Microbes pages 1-12. Published online at DOI: http://dx.doi.org/10.3920/BM2015.0006.
Blatchford P, Stoklosinski H, Walton G, Swann J, Gibson G, Gearry R, Ansell J 2015b. Kiwifruit fermentation drives positive gut microbial and metabolic changes irrespective of initial microbiota composition. Bioactive Carbohydrates and Dietary Fibre 6(1): 37-45.
Boland, M.J., Hardman, M.J. 1972. Kinetic studies on the thiol protease from Actinidia chinensis. FEBS Letters, 27(2): 282-284.
Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108: 16050-5.
Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nature Reviews Immunology. 2013; 13: 790-801.
Candela M, Rampelli S, Turroni S, Severgnini M, Consolandi C, De Bellis G, et al. Unbalance of intestinal microbiota in atopic children. BMC Microbiology. 2012; 12: 95.
Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R. PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics. 2010; 26: 266-7.
Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nature Methods. 2010; 7: 335-6.
Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108 Suppl 1: 4516-22.
Cardona F, Andres-Lacueva C, Tulipani S, Tinahones FJ, Queipo-Ortuno MI. 2013. Benefits of polyphenols on gut microbiota and implications in human health. Journal of Nutritional Biochemistry, 24: 1415-1422.
Chan AO, Leung G, Tong T, Wong NY. Increasing dietary fiber intake in terms of kiwifruit improves constipation in Chinese patients. World Journal of Gastroenterology: WJG. 2007; 13: 4771-5.
Chang C, Lin T, Lu Y, Liu T, Liu J. 2010. Kiwifruit improves bowel function in patients with irritable bowel syndrome with constipation. Asia Pacific Journal of Clinical Nutrition 19(4): 451-457.
Chassard, C, Dapoigny, M, Scott, KP, Crouzet, L, Del’homme, C, Marquet, P, Martin, JC, Pickering, G, Ardid, D, Eschalier, A, Dubray, C, Flint, HJ and Bernalier-Donadille, A. 2012. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 35: 828-838.
Chen W, Liu F, Ling Z, Tong X, Xiang C 2012. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PloS One 7(6): e39743.
DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl. Environ. Microbiol. 2006; 72: 5069-72.
de Sousa Moraes LF, Grzeskowiak LM, de Sales Teixeira TF, Gouveia Peluzio Mdo C 2014. Intestinal microbiota and probiotics in celiac disease. Clinical Microbiology Reviews 27(3): 482-9.
de Vos WM, de Vos EA 2012. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutrition Reviews 70 Suppl 1: S45-56.
de Weerth C, Fuentes S, Puylaert P, de Vos WM 2013. Intestinal microbiota of infants with colic: development and specific signatures. Pediatrics 131(2): e550-8.
Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG 2008. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. Journal of Psychiatric Research 43(2): 164-74.
Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006; 130: 1377-90.
Drummond L. 2013. The composition and nutritional value of kiwifruit. Advances in Food and Nutrition Research 68: 33-57.
Drummond L, Gearry RB. 2013. Kiwifruit modulation of gastrointestinal motility. Advances in Food and Nutrition Research 68: 219-232.
Duncan SH, Hold GL, Harmsen HJ, Stewart CS, Flint HJ. Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. International Journal of Systematic and Evolutionary Microbiology. 2002; 52: 2141-6.
Duncan SH, Louis P, Flint HJ. Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl. Environ. Microbiol. 2004; 70: 5810-7.
Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010; 26: 2460-1.
Egert M, de Graaf AA, Smidt H, de Vos WM, Venema K. Beyond diversity: functional microbiomics of the human colon. Trends in Microbiology. 2006; 14: 86-91.
Eidenberger T, Selg M, Fuerst S, Krennhuber K. 2014. In-vitro inhibition of human lipase PS by polyphenols from kiwi fruit. Journal of Food Research. 3(4): 71-77.
Ferguson AR, Ferguson LR. Are kiwifruit really good for you? In: Huang HW, editor. Proceedings of the Fifth International Symposium on Kiwifruit. 2003. 131-8.
Flint HJ, Bayer EA, Rincon MT, Lamed R, White BA 2008. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol 6(2): 121-31.
Fu CJ, Carter JN, Li Y, Porter JH, Kerley MS 2006. Comparison of agar plate and real-time PCR on enumeration of Lactobacillus, Clostridium perfringens and total anaerobic bacteria in dog faeces. Letters in Applied Microbiology 42(5): 490-494.
Fujimoto T, Imaeda H, Takahashi K, Kasumi E, Bamba S, Fujiyama Y, Andoh A 2013. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gastroenterol Hepatol 28(4): 613-9.
Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010; 59: 3049-57.
Gibson GR, Scott KP, Rastall RA, Tuohy KM, Hotchkiss A, Dubert-Ferrandon A, Gareau M, Murphy EF, Sulnier D, Loh G, MacFarlane S, Delzenne N, Ringel Y, Kozianowski G, Dickmann R, Lenoir-Wijnkoop I, Walker C, Buddington R. 2010. Dietary prebiotics: current status and new definition. Food Science and Technology Bulletin: Functional Foods, 7: 1-19.
Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Beneficial Microbes. 2014; 5: 3-17.
Gostner A, Blaut M, Schaffer V, Kozianowski G, Theis S, Klingeberg M, et al. Effect of isomalt consumption on faecal microflora and colonic metabolism in healthy volunteers. Br. J. Nutr. 2006; 95: 40-50.
Guidance for industry: irritable bowel syndrome - clinical evaluation of drugs for treatment. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. http://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf
Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: The role of butyrate on colonic function. Aliment. Pharmacol. Ther. 2008; 27: 104-19.
Hazenberg MP, van de Merwe JP, Pena AS, Pennock-Schroder AM, van Lieshout LM. Antibodies to Coprococcus comes in sera of patients with Crohn's disease. Isolation and purification of the agglutinating antigen tested with an ELISA technique. Journal of Clinical & Laboratory Immunology. 1987; 23: 143-8.
Herlemann DPR, Labrenz M, Juergens K, Bertilsson S, Waniek JJ, Andersson AF. Transitions in bacterial communities along the 2000 km salinity gradient of the Baltic Sea. ISME Journal. 2011; 5: 1571-9.
Hold GL, Pryde SE, Russell VJ, Furrie E, Flint HJ 2002. Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis. FEMS Microbiol Ecol 39(1): 33-9.
Huda-Faujan N, Abdulamir AS, Fatimah AB, Anas OM, Shuhaimi M, Yazid AM, et al. The impact of the level of the intestinal short chain fatty acids in inflammatory bowel disease patients versus healthy subjects. The Open Biochemistry Journal. 2010; 4: 53-8.
Hudcovic T, Kolinska J, Klepetar J, Stepankova R, Rezanka T, Srutkova D, et al. Protective effect of Clostridium tyrobutyricum in acute dextran sodium sulphate-induced colitis: differential regulation of tumour necrosis factor-alpha and interleukin-18 in BALB/c and severe combined immunodeficiency mice. Clinical and Experimental Immunology. 2012; 167: 356-65.
Husebye E, Hellstrom PM, Sundler F, Chen J, and Midtvedt T. 2001. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. American Journal of Physiology, Gastrointestinal and Liver Physiology 280: G368-G380.
Hunter DC, Skinner MA, Wolber FM, Booth CL, Loh JMS, Wohlers M, Stevenson LM, Kruger MC. 2012. Consumption of gold kiwifruit reduces severity and duration of selected upper respiratory tract infection symptoms and increases plasma vitamin C concentration in healthy older adults. British Journal of Nutrition 108: 1235- 1245.
Jeffery IB, O'Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, Simren M 2012.An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota.Gut 61(7): 997-1006.
Kalliomaki M, Satokari R, Lahteenoja H, Vahamiko S, Gronlund J, Routi T, Salminen S 2012.Expression of microbiota, Toll-like receptors, and their regulators in the small intestinal mucosa in celiac disease.Journal of Pediatric Gastroenterology and Nutrition 54(6): 727-32.
L Kaur, SM Rutherfurd, PJ Moughan, L Drummond, and MJ Boland.2010.Actinidin enhances protein digestion in the small intestine as assessed using an in vitro digestion model, J. Agric.Food Chem.58 (8): 5074-5080.
Khalif IL, Quigley EMM, Konovitch EA and Maximova ID.2005.Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation.Digestive and Liver Disease 37: 838-849.
Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL 2013.Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.Nature Medicine 19(5): 576-85.
Kok RG, DeWaal A, Schut F, Welling GW, Weenk G, Hellingwerf KJ 1996.Specific detection and analysis of a probiotic Bifidobacterium strain in infant feces.Applied and Environmental Microbiology 62(10): 3668-3672.
Kolida S, Gibson GR.2007.Prebiotic capacity of inulin-type fructans.The Journal of Nutrition, 137(11): 2503S-2506S.
Kolida S, Meyer D, Gibson GR.A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans.Eur.J. Clin.Nutr.2007; 61: 1189-95.
Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V, Behre CJ, Knight R, Fagerberg B, Ley RE, Backhed F 2011.Human oral, gut, and plaque microbiota in patients with atherosclerosis.Proceedings of the National Academy of Sciences of the United States of America 108 Suppl 1: 4592-8.
Kurakawa T, Ogata K, Matsuda K, Tsuji H, Kubota H, Takada T, Kado Y, Asahara T, Takahashi T, Nomoto K 2015.Diversity of Intestinal Clostridium coccoides group in the Japanese population, as demonstrated by reverse transcription-quantitative PCR.PLoS One 10(5): e0126226.
Leahy SC, Kelly WJ, Altermann E, Ronimus RS, Yeoman CJ, Pacheco DM, Li D, Kong Z, McTavish S, Sang C, Lambie SC, Janssen PH, Dey D, Attwood GT 2010.The genome sequence of the rumen methanogen Methanobrevibacter ruminantium reveals new possibilities for controlling ruminant methane emissions.PLoS One 5(1).
Lee YK, Menezes JS, Umesaki Y, Mazmanian SK 2011.Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis.Proceedings of the National Academy of Sciences of the United States of America 108 Suppl 1: 4615-22.
Lepage P, Hasler R, Spehlmann ME, Rehman A, Zvirbliene A, Begun A, Ott S, Kupcinskas L, Dore J, Raedler A, Schreiber S 2011.Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis.Gastroenterology 141(1): 227-36.
Leung L, Riutta T, Kotecha J, Rosser W. 2011.Chronic constipation: An evidence-based review.The Journal of the American Board of Family Medicine 24(4): 436-451.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI 2006.Microbial ecology - Human gut microbes associated with obesity.Nature 444(7122): 1022-1023.
Liu LWC.2011.Chronic constipation: current treatment options.Canadian Journal of Gastroenterology 25(Suppl B): 22B-28B.
Louis P, Flint HJ 2009.Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine.FEMS Microbiol Lett 294(1): 1-8.
Maccaferri S, Candela M, Turroni S, Centanni M, Severgnini M, Consolandi C, Cavina P, Brigidi P 2012.IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation.Gut Microbes 3(5): 406-13.
Macfarlane GT, Macfarlane S. Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics.J. Clin.Gastroenterol.2011; 45 Suppl: S120-7.
R Maddumage, NJ Nieuwenhuizen, SM Bulley, JM Cooney, SA Green, RG Atkinson.2013.Diversity and relative levels of actinidin, kiwellin, and thaumatin-like allergens in 15 varieties of kiwifruit (Actinidia).J. Agric.Food Chem.61: 728-739.
Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD.PANDAseq: PAired-eND Assembler for Illumina sequences.BMC Bioinformatics.2012; 13:31.
Matsuki T, Watanabe K, Fujimoto J, Miyamoto Y, Takada T, Matsumoto K, Oyaizu H, Tanaka R 2002.Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces.Appl Environ Microbiol 68(11): 5445-51.
Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG.Simplified assessment of segmental colonic transit.Gastroenterology.1987; 92: 40-7.
Millet S, Van Oeckel MJ, Aluwe M, Delezie E, De Brabander DL.Prediction of in vivo short-chain fatty acid production in hindgut fermenting mammals: problems and pitfalls.Crit.Rev. Food Sci.Nutr.2010; 50:605-19.
Miquel S, Martin R, Rossi O, Bermudez-Humaran LG, Chatel JM, Sokol H, et al.Faecalibacterium prausnitzii and human intestinal health.Current Opinion in Microbiology.2013; 16: 255-61.
Monro JA, Mishra S, Venn B. 2010.Baselines representing blood glucose clearance improve in vitro prediction of the glycaemic impact of customarily consumed food quantities.British Journal of Nutrition, 103(2): 295-305.
Murata Y, Ohmori H, Ichikawa M, Harada A, Agari M, Fukuba H, Yamasaki M, Yasuzawa M, Takemoto M, Ikeda M, Matsumoto N, Tamura T, Sumimoto R, Namba K 2013.Fecal microbiota and fecal characteristics of patients with Parkinson's disease.Journal of Intestinal Microbiology 27(4): 211-215.
Nadkarni MA, Martin FE, Jacques NA, Hunter N 2002.Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set.Microbiology-Sgm 148: 257-266.
Neufeld KM, Kang N, Bienenstock J, Foster JA 2011.Reduced anxiety-like behavior and central neurochemical change in germ-free mice.Neurogastroenterology and Motility 23(3): 255-64, e119.
NJ Nieuwenhuizen, R Maddumage, GK Tsang, LG Fraser, JM Cooney, HN De Silva, S Green, KA Richardson, RG Atkinson.2012.Mapping, complementation, and targets of the cysteine protease actinidin in kiwifruit.Plant Physiology 158(1): 376-388.
Parkar SG, Rosendale D, Paturi G, Herath TD, Stoklosinski H, Phipps JE, et al.In vitro utilization of gold and green kiwifruit oligosaccharides by human gut microbial populations.Plant Foods for Human Nutrition.2012; 67: 200-7.
Parnell JA, Reimer RA.Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp rats.The British Journal of Nutrition.2012; 107: 601-13.
Paturi G, Butts CA, Bentley-Hewitt KL, Ansell J 2014.Influence of green and gold kiwifruit on indices of large bowel function in healthy rats.J Food Sci 79(8): H1611-20.
Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ.The microbiology of butyrate formation in the human colon.FEMS Microbiology Letters.2002; 217: 133-9.
Qin JJ, Li RQ, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al.A human gut microbial gene catalogue established by metagenomic sequencing.Nature.2010; 464: 59-U70.
R Development Core Team 2008.R: A language and environment for statistical computing.R Foundation for Statistical Computing, Vienna, Austria..
RStudio.RStudio: Integrated development environment for R (Version 0.97.551) Computer software.Boston, MA.http://www.rstudio.org/.2012.
Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, et al.Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome.Gastroenterology.2011; 141: 1792-801.
Rajilic-Stojanovic M, de Vos WM.The first 1000 cultured species of the human gastrointestinal microbiota.FEMS Microbiology Reviews.2014; 38: 996-1047.
Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P 2009.Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii.British Journal of Nutrition 101(4): 541-550.
Rawls JF, Mahowald MA, Ley RE, Gordon JI.Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection.Cell.2006; 127: 423-33.
Reid G 1999.The scientific basis for probiotic strains ofLactobacillus.Appl Environ Microbiol 65(9): 3763-6.
Rhee SH, Pothoulakis C, and Mayer EA.2009.Principles and clinical implications of the brain-gut-enteric microbiota axis.Nature Reviews Gastroenterology & Hepatology 6: 306-314.
Richardson AJ, Calder AG, Stewart CS, Smith A. 1989.Simultaneous determination of volatile and non-volatile acidic fermentation products of anaerobes by capillary gas-chromatography.Lett.Appl.Microbiol.9: 5-8.
Rigottier-Gois L. 2013.Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis.The ISME Journal 7: 1256-1261.
Rinttila T, Kassinen A, Malinen E, Krogius L, Palva A 2004.Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR.Journal of Applied Microbiology 97(6): 1166-1177.
Rosendale DI, Maddox IS, Miles MC, Rodier M, Skinner M, Sutherland J. 2008.High-throughput microbial bioassays to screen potential New Zealand functional food ingredients intended to manage the growth of probiotic and pathogenic gut bacteria.International Journal of Food Science and Technology, 43(12): 2257-2267.
Rumah KR, Linden J, Fischetti VA, Vartanian T 2013.Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease.PloS One 8(10): e76359.
Rush EC, Patel M, Plank LD, Ferguson LR.2002.Kiwifruit promotes laxation in the elderly.Asia Pacific Journal of Clinical Nutrition 11(2): 164-168.
Sanchez B, Champomier-Verges MC, Collado Mdel C, Anglade P, Baraige F, Sanz Y, et al.Low-pH adaptation and the acid tolerance response of Bifidobacterium longum biotype longum.Appl.Environ.Microbiol.2007; 73: 6450-9.
Sartor RB.Efficacy of probiotics for the management of inflammatory bowel disease.Gastroenterology & Hepatology.2011; 7: 606-8.
Saulnier DM, Spinler JK, Gibson GR, Versalovic J. Mechanisms of probiosis and prebiosis: considerations for enhanced functional foods.Curr.Opin.Biotechnol.2009; 20: 135-41.
Savino F, Pelle E, Palumeri E, Oggero R, Miniero R 2007.Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study.Pediatrics 119(1): e124-30.
Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P 2014.Gut microbiota are related to Parkinson's disease and clinical phenotype.Movement Disorders.
Schloss PD, Schubert AM, Zackular JP, Iverson KD, Young VB, Petrosino JF.Stabilization of the murine gut microbiome following weaning.Gut Microbes.2012; 3: 383-93.
Seeram N. Associate Professor of Bioactive Botanical Research Laboratory, University of Rhode Island.Digestive Health Forum, NutraIngredients-USA, 25 September 2014.
Singleton, Vernon L, Orthofer, Rudolf, Lamuela-Raventos, Rosa M. 1999.Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent 299: 152.
Skinner MA.2012.Wellness foods based on the health benefits of fruit: gold kiwifruit for immune support and reducing symptoms of colds and influenza.Journal of Food and Drug Analysis 20(1): 261-264.
Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, et al.Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.Proc.Natl.Acad.Sci.USA.2008; 105: 16731-6.
Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, et al.Low counts of Faecalibacterium prausnitzii in colitis microbiota.Inflammatory Bowel Diseases.2009; 15: 1183-9.
Stonehouse W, Gammon CS, Beck KL, Conlon CA, Von Hurst PR, Kruger R. 2012.Kiwifruit: our daily prescription for health.Canadian Journal of Physiology and Pharmacology 91(6): 442-447.
D Sun-Waterhouse, I Wen, R Wibisono, LD Melton, S Wadhwa.2009.Evaluation of the extraction efficiency for polyphenol extracts from by‐products of green kiwifruit juicing.International Journal of Food Science & Technology.44(12): 2644-2652.
Taras D, Simmering R, Collins MD, Lawson PA, Blaut M. Reclassification of Eubacterium formicigenerans Holdeman and Moore 1974 as Dorea formicigenerans gen. nov., comb. nov., and description of Dorea longicatena sp. nov., isolated from human faeces.International Journal of Systematic and Evolutionary Microbiology.2002; 52: 423-8.
Timm D, Willis H, Thomas W, Sanders L, Boileau T, Slavin J. The use of a wireless motility device (SmartPill(R)) for the measurement of gastrointestinal transit time after a dietary fibre intervention.The British Journal of Nutrition.2011; 105: 1337-42.
Tuohy KM, Kolida S, Lustenberger AM, Gibson GR.The prebiotic effects of biscuits containing partially hydrolysed guar gum and fructo-oligosaccharides--a human volunteer study.The British Journal of Nutrition.2001; 86: 341-8.
Turnbaugh PJ, Baeckhed F, Fulton L, Gordon JI 2008.Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome.Cell Host & Microbe 3(4): 213-223.
Udani J, Bloom D. 2013.Effects of kivia powder on Gut health in patients with occasional constipation: a randomized, double-blind, placebo-controlled study.Nutrition Journal 12(1): 78.
Vaahtovuo J, Munukka E, Korkeamaki M, Luukkainen R, Toivanen P 2008.Fecal microbiota in early rheumatoid arthritis.Journal of Rheumatology 35(8): 1500-5.
Vogt JA, Pencharz PB, Wolever TMS.L-Rhamnose increases serum propionate in humans.American Journal of Clinical Nutrition.2004; 80: 89-94.
Walker AW, Duncan SH, McWilliam Leitch EC, Child MW, Flint HJ. pH and peptide supply can radically alter bacterial populations and short-chain fatty acid ratios within microbial communities from the human colon.Appl.Environ.Microbiol.2005; 71: 3692-700.
Walker AW, Duncan SH, Harmsen HJ, Holtrop G, Welling GW, Flint HJ 2008.The species composition of the human intestinal microbiota differs between particle-associated and liquid phase communities.Environ Microbiol 10(12): 3275-83.
Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, et al.Dominant and diet-responsive groups of bacteria within the human colonic microbiota.ISME Journal.2011; 5: 220-30.
Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA 2011.Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism.Applied and Environmental Microbiology 77(18): 6718-21.
Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L 2012.Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers.ISME Journal 6(2): 320-9.
Wang Q, Garrity GM, Tiedje JM, Cole JR.Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy.Appl.Environ.Microbiol.2007; 73: 5261-7.
Williams BL, Hornig M, Parekh T, Lipkin WI 2012.Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. mBio 3(1).
Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, et al.A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes.Gastroenterology.2010; 139: 1844-54 e1.
Wong JMW, de Souza R, Kendall CWC, Emam A, Jenkins DJA.Colonic health: Fermentation and short chain fatty acids.Journal of Clinical Gastroenterology.2006; 40: 235-43.
Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al.Linking long-term dietary patterns with gut microbial enterotypes.Science.2011; 334: 105-8.
Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, Yu P, Zhao C, Li L, Zhou A, Wang J, Moore JE, Millar BC, Xu J 2010.Molecular characterisation of the faecal microbiota in patients with type II diabetes.Current Microbiology 61(1): 69-78.
Ze X, Duncan SH, Louis P, Flint HJ.Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon.ISME Journal.2012; 6: 1535-43.
Zoppi G, Cinquetti M, Luciano A, Benini A, Miner A, and Bertazzoni ME.1998.The intestinal ecosystem in chronic functional constipation.Acta Paediatrica 87: 836-841.
Claims (15)
- 乾燥させたゴールドキウイフルーツから調製される医薬組成物であって、
前記乾燥させたゴールドキウイフルーツは、アクティニディア・キネンシスZesy002キウイフルーツであり、
便秘の1つ以上の症状を有する対象者の消化管におけるフィーカリバクテリウム・プラウスニッツィイのレベルの増加を目的とした医薬組成物。 - 請求項1に記載の医薬組成物であって、腸内投与、経口投与、または直腸投与用に処方された医薬組成物。
- 請求項1または請求項2に記載の医薬組成物であって、錠剤、カプセル、液状、ゼリー、または分包のうちの1つ以上として処方された医薬組成物。
- 請求項1~請求項3のいずれか1項に記載の医薬組成物であって、
(i)一日あたり2000~4000mgの粉末、またはそれと同価の液体、
(ii)一日あたり250~2500mgの粉末、またはそれと同価の液体、
(iii)一日あたり約2400mgの粉末、またはそれと同価の液体、あるいは、
(iv)一日あたり約600mgの粉末、またはそれと同価の液体
の投与量での投与用に処方された医薬組成物。 - 請求項1~請求項4のいずれか1項に記載の医薬組成物であって、
(i)更なる消化補助剤、
(ii)1つ以上のプロバイオティクス、プレバイオティクス、またはシンバイオティクス組成物、あるいは、
(iii)食物繊維および/または消化酵素
のうちの1つ以上との同時投与用に処方された医薬組成物。 - 請求項1~請求項5のいずれか1項に記載の医薬組成物であって、ポリフェノールがさらに補足された医薬組成物。
- 請求項1~6のいずれか1項に記載の医薬組成物であって、ゲルカプセルとして処方された医薬組成物。
- 乾燥させたゴールドキウイフルーツから調製される医薬組成物であって、
前記乾燥させたゴールドキウイフルーツは、アクティニディア・キネンシスZesy002キウイフルーツであり、
便秘の1つ以上の症状を有する対象者の消化管におけるフィーカリバクテリウム・プラウスニッツィイのレベルの低下を改善又はレベルを維持することを目的とした医薬組成物。 - 請求項8に記載の医薬組成物であって、腸内投与、経口投与、または直腸投与用に処方された医薬組成物。
- 請求項8または請求項9に記載の医薬組成物であって、錠剤、カプセル、液体、ゼリー、または分包のうちの1つ以上としての投与用に処方された医薬組成物。
- 請求項8~請求項10のいずれか1項に記載の医薬組成物であって、
(i)一日あたり2000~4000mgの粉末、またはそれと同価の液体、
(ii)一日あたり250~2500mgの粉末、またはそれと同価の液体、
(iii)一日あたり約2400mgの粉末、またはそれと同価の液体、あるいは、
(iv)一日あたり約600mgの粉末、またはそれと同価の液体
の投与量での投与用に処方された医薬組成物。 - 請求項8~請求項11のいずれか1項に記載の医薬組成物であって、
(i)更なる消化補助剤、
(ii)プロバイオティクス、プレバイオティクス、またはシンバイオティクス組成物、あるいは、
(iii)食物繊維および/または消化酵素
のうちの1つ以上との同時投与用に処方された医薬組成物。 - 請求項8~請求項12のいずれか1項に記載の医薬組成物であって、ポリフェノールがさらに補足された医薬組成物。
- 請求項8~請求項13のいずれか1項に記載の医薬組成物であって、ゲルカプセルとして処方された医薬組成物。
- 請求項1~請求項7のいずれか1項又は請求項8~請求項14のいずれか1項に記載の医薬組成物であって、前記対象者は、腸不規則性、クローン病、潰瘍性大腸炎、過敏性腸症候群、炎症性腸疾患、または胃腸がんのうちの1つ以上の症状もまた有している、医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022017185A JP7471668B2 (ja) | 2014-11-28 | 2022-02-07 | ゴールドキウイフルーツ組成物ならびにその調製および使用方法 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ702454 | 2014-11-28 | ||
NZ70245414 | 2014-11-28 | ||
NZ70640515 | 2015-03-27 | ||
NZ706405 | 2015-03-27 | ||
PCT/NZ2015/050200 WO2016085356A1 (en) | 2014-11-28 | 2015-11-27 | Gold kiwifruit compositions and methods of preparation and use therefor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022017185A Division JP7471668B2 (ja) | 2014-11-28 | 2022-02-07 | ゴールドキウイフルーツ組成物ならびにその調製および使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017537156A JP2017537156A (ja) | 2017-12-14 |
JP2017537156A5 JP2017537156A5 (ja) | 2019-01-10 |
JP7330667B2 true JP7330667B2 (ja) | 2023-08-22 |
Family
ID=56074755
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017547368A Active JP7330667B2 (ja) | 2014-11-28 | 2015-11-27 | ゴールドキウイフルーツ組成物ならびにその調製および使用方法 |
JP2022017185A Active JP7471668B2 (ja) | 2014-11-28 | 2022-02-07 | ゴールドキウイフルーツ組成物ならびにその調製および使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022017185A Active JP7471668B2 (ja) | 2014-11-28 | 2022-02-07 | ゴールドキウイフルーツ組成物ならびにその調製および使用方法 |
Country Status (10)
Country | Link |
---|---|
US (4) | US10512663B2 (ja) |
EP (1) | EP3223838A4 (ja) |
JP (2) | JP7330667B2 (ja) |
KR (2) | KR102599549B1 (ja) |
CN (3) | CN116763830A (ja) |
BR (1) | BR112017011078B1 (ja) |
CA (2) | CA3200468A1 (ja) |
MY (1) | MY188290A (ja) |
NZ (1) | NZ732197A (ja) |
WO (1) | WO2016085356A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3200468A1 (en) * | 2014-11-28 | 2016-06-02 | Anagenix Ip Limited | Gold kiwifruit compositions and methods of preparation and use therefor |
KR101833503B1 (ko) * | 2016-12-26 | 2018-03-05 | 주식회사 엠디헬스케어 | 만성폐쇄성폐질환자에서 세균 메타게놈 분석을 통한 폐암 진단방법 |
KR101833348B1 (ko) * | 2016-12-26 | 2018-03-02 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 유방암 진단방법 |
KR101940426B1 (ko) * | 2016-12-28 | 2019-01-18 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 대장종양 진단 방법 |
KR101942197B1 (ko) * | 2016-12-28 | 2019-01-24 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 전립선질환 진단 방법 |
US11413318B2 (en) * | 2017-06-06 | 2022-08-16 | Sami-Sabinsa Group Limited | Compositions and methods for management of atrophic gastritis and colitis |
US10881675B2 (en) | 2017-10-11 | 2021-01-05 | Jennifer L. Gu | Gut health compositions |
KR102130485B1 (ko) * | 2017-10-13 | 2020-07-06 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 알츠하이머치매 진단방법 |
KR102007786B1 (ko) * | 2017-10-18 | 2019-08-07 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 두경부암 진단방법 |
WO2019118984A2 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
KR101940950B1 (ko) * | 2018-01-23 | 2019-01-21 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 담관암 진단방법 |
KR101944662B1 (ko) * | 2018-02-14 | 2019-02-01 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 뇌졸중 진단방법 |
US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
EP3846830A4 (en) | 2018-09-05 | 2022-07-06 | Solarea Bio, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES |
CN109288104B (zh) * | 2018-11-12 | 2023-09-01 | 方家铺子(莆田)绿色食品有限公司 | 一种桂圆鲜果挂黄处理设备及其处理方法 |
SG11202107687VA (en) | 2019-01-18 | 2021-08-30 | Cp Kelco U S Inc | Prebiotic composition and its use |
CN110279814A (zh) * | 2019-06-10 | 2019-09-27 | 湖北虹玮农业有限公司 | 一种用于中老年慢性便秘的功能食品 |
US11684645B2 (en) * | 2019-11-26 | 2023-06-27 | Tci Co., Ltd. | Actinidia chinensis Planch ferment and use thereof |
WO2022115709A2 (en) * | 2020-11-30 | 2022-06-02 | January, Inc. | Methods and composition for treating metabolic syndrome |
US20220233151A1 (en) * | 2021-01-22 | 2022-07-28 | Ethicon Llc | Bariatric surgery post-surgical monitoring |
KR102543549B1 (ko) * | 2021-01-26 | 2023-06-15 | 주식회사 다솔마임마케팅사업부 | 칼라만시 발포정 및 그 제조 방법 |
CN113521109A (zh) * | 2021-06-28 | 2021-10-22 | 广州知易生物科技有限公司 | 解纤维素拟杆菌在预防和/或治疗炎症性肠病中的应用 |
US20230144246A1 (en) * | 2021-11-05 | 2023-05-11 | Tci Co., Ltd. | Probiotic composition and its method for improving intestinal tract of subject in need thereof |
CN116076711A (zh) * | 2021-11-05 | 2023-05-09 | 百岳特生物技术(上海)有限公司 | 益生质组合物及其用途 |
WO2023092150A1 (en) | 2021-11-22 | 2023-05-25 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
KR102536627B1 (ko) * | 2022-09-30 | 2023-05-30 | (주)바이텍 | 키위 발효물을 포함하는 알코올성 간손상 예방 또는 개선용 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US22355A (en) | 1858-12-21 | sherwood | ||
JP3246296B2 (ja) | 1995-11-09 | 2002-01-15 | 宇部興産株式会社 | 半溶融金属の成形方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2750767B2 (ja) * | 1990-02-21 | 1998-05-13 | 雪印乳業株式会社 | 新規糖アルコール |
CN1107308A (zh) * | 1994-02-25 | 1995-08-30 | 中国癌症研究基金会 | 猕猴桃天然营养口服液 |
JPH10313822A (ja) | 1997-05-20 | 1998-12-02 | Pola Chem Ind Inc | 腸内細菌叢改善剤及びそれを含有する組成物 |
AT503521A1 (de) * | 2006-05-05 | 2007-11-15 | Omnica Gmbh | Verwendung eines extraktes von kiwi-frucht |
USPP22355P3 (en) * | 2009-06-30 | 2011-12-20 | Zespri Group Limited | Kiwifruit plant named ‘ZESY002’ |
CA2787544C (en) * | 2010-01-28 | 2019-07-09 | Ab-Biotics S.A. | Probiotic composition for use in the treatment of bowel inflammation |
CA3200468A1 (en) * | 2014-11-28 | 2016-06-02 | Anagenix Ip Limited | Gold kiwifruit compositions and methods of preparation and use therefor |
-
2015
- 2015-11-27 CA CA3200468A patent/CA3200468A1/en active Pending
- 2015-11-27 CN CN202310572047.4A patent/CN116763830A/zh active Pending
- 2015-11-27 CN CN201580064171.3A patent/CN106999523A/zh active Pending
- 2015-11-27 NZ NZ732197A patent/NZ732197A/en unknown
- 2015-11-27 BR BR112017011078-4A patent/BR112017011078B1/pt active IP Right Grant
- 2015-11-27 JP JP2017547368A patent/JP7330667B2/ja active Active
- 2015-11-27 KR KR1020177017760A patent/KR102599549B1/ko active IP Right Grant
- 2015-11-27 WO PCT/NZ2015/050200 patent/WO2016085356A1/en active Application Filing
- 2015-11-27 US US15/529,734 patent/US10512663B2/en active Active
- 2015-11-27 MY MYPI2017701750A patent/MY188290A/en unknown
- 2015-11-27 KR KR1020237037806A patent/KR20230156436A/ko active Application Filing
- 2015-11-27 EP EP15863825.4A patent/EP3223838A4/en active Pending
- 2015-11-27 CA CA2967263A patent/CA2967263A1/en active Pending
- 2015-11-27 CN CN202310308827.8A patent/CN116270773A/zh active Pending
-
2019
- 2019-11-06 US US16/675,936 patent/US11090348B2/en active Active
-
2021
- 2021-06-11 US US17/345,478 patent/US11642386B2/en active Active
-
2022
- 2022-02-07 JP JP2022017185A patent/JP7471668B2/ja active Active
-
2023
- 2023-03-22 US US18/188,045 patent/US20240091291A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US22355A (en) | 1858-12-21 | sherwood | ||
JP3246296B2 (ja) | 1995-11-09 | 2002-01-15 | 宇部興産株式会社 | 半溶融金属の成形方法 |
Non-Patent Citations (3)
Title |
---|
Current Opinion in Microbiology,2013,16,p.1-7 |
J.Food Sci.,2014,Vol.79,No.8,p.H1611-1620 |
Korean J.Plant Res.,2011,24(1),p.61-68 |
Also Published As
Publication number | Publication date |
---|---|
US10512663B2 (en) | 2019-12-24 |
US20170326190A1 (en) | 2017-11-16 |
NZ732197A (en) | 2022-07-01 |
JP2022078050A (ja) | 2022-05-24 |
JP7471668B2 (ja) | 2024-04-22 |
BR112017011078A2 (pt) | 2017-12-26 |
KR20170088970A (ko) | 2017-08-02 |
CN106999523A (zh) | 2017-08-01 |
MY188290A (en) | 2021-11-25 |
CN116270773A (zh) | 2023-06-23 |
US20220105145A1 (en) | 2022-04-07 |
BR112017011078B1 (pt) | 2021-05-11 |
CA3200468A1 (en) | 2016-06-02 |
KR102599549B1 (ko) | 2023-11-06 |
JP2017537156A (ja) | 2017-12-14 |
US11642386B2 (en) | 2023-05-09 |
CN116763830A (zh) | 2023-09-19 |
US20200197460A1 (en) | 2020-06-25 |
KR20230156436A (ko) | 2023-11-14 |
WO2016085356A1 (en) | 2016-06-02 |
EP3223838A1 (en) | 2017-10-04 |
CA2967263A1 (en) | 2016-06-02 |
US20240091291A1 (en) | 2024-03-21 |
US11090348B2 (en) | 2021-08-17 |
EP3223838A4 (en) | 2018-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7471668B2 (ja) | ゴールドキウイフルーツ組成物ならびにその調製および使用方法 | |
JP7168558B2 (ja) | Clostridium difficile感染症の処置 | |
Xiao et al. | Lactic acid bacteria in health and disease | |
EP2827725A1 (en) | Probiotic derived non-viable material for infection prevention and treatment | |
Moens et al. | Lactobacillus rhamnosus GG and Saccharomyces cerevisiae boulardii exert synergistic antipathogenic activity in vitro against enterotoxigenic Escherichia coli | |
JP7360420B2 (ja) | ディスバイオシスの治療のために用いられるブドウ果皮 | |
KR20210057748A (ko) | 장내 마이크로바이옴의 이상 조성 또는 기능과 관련된 장애 치료용 프리바이오틱 | |
WO2008136689A1 (en) | Kiwifruit compositions | |
Wang et al. | Dietary intervention with α-amylase inhibitor in white kidney beans added yogurt modulated gut microbiota to adjust blood glucose in mice | |
CA3223260A1 (en) | Probiotic composition for the treatment of increased intestinal permeability | |
CN111565734A (zh) | 植物乳杆菌的治疗用途 | |
US20230310519A1 (en) | Use of adlercreutzia bacteria for the treatment of inflammatory diseases | |
Hussein et al. | Developments on the applications and the suitability of functional fermented Sour Sobya as a viable source of novel probiotics in the managements of gastrointestinal disorders and blood lipid profiles | |
SP | Effects of Resveratrol in a Mouse Model of Alcohol Addiction | |
RU2772025C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ Lactobacillus plantarum | |
Ansell | RELATED APPLICATIONS | |
CN118159279A (zh) | 用于调节肠道微生物组的益生菌组合物 | |
WO2021067167A1 (en) | Clostrodioides difficile treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181126 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190903 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200609 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210323 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210622 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210823 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211005 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230809 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7330667 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |